Activation of human NK cells and monocytes with cisplatin in vitro

Ajit Sodhi, Kalpana Pai, Rakesh Kumar Singh, Sukh Mahendra Singh

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-γ enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-γ treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-γ and were subsequently treated with cisplatin.

Original languageEnglish (US)
Pages (from-to)893-898
Number of pages6
JournalInternational Journal of Immunopharmacology
Volume12
Issue number8
DOIs
StatePublished - 1990

Fingerprint

Natural Killer Cells
Cisplatin
Monocytes
K562 Cells
Cell Line
In Vitro Techniques
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Activation of human NK cells and monocytes with cisplatin in vitro. / Sodhi, Ajit; Pai, Kalpana; Singh, Rakesh Kumar; Singh, Sukh Mahendra.

In: International Journal of Immunopharmacology, Vol. 12, No. 8, 1990, p. 893-898.

Research output: Contribution to journalArticle

Sodhi, Ajit ; Pai, Kalpana ; Singh, Rakesh Kumar ; Singh, Sukh Mahendra. / Activation of human NK cells and monocytes with cisplatin in vitro. In: International Journal of Immunopharmacology. 1990 ; Vol. 12, No. 8. pp. 893-898.
@article{5d2f2dba9c8b4c30a97896858cb0a2d0,
title = "Activation of human NK cells and monocytes with cisplatin in vitro",
abstract = "Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-γ enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-γ treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-γ and were subsequently treated with cisplatin.",
author = "Ajit Sodhi and Kalpana Pai and Singh, {Rakesh Kumar} and Singh, {Sukh Mahendra}",
year = "1990",
doi = "10.1016/0192-0561(90)90008-B",
language = "English (US)",
volume = "12",
pages = "893--898",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Activation of human NK cells and monocytes with cisplatin in vitro

AU - Sodhi, Ajit

AU - Pai, Kalpana

AU - Singh, Rakesh Kumar

AU - Singh, Sukh Mahendra

PY - 1990

Y1 - 1990

N2 - Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-γ enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-γ treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-γ and were subsequently treated with cisplatin.

AB - Human natural killer (NK) cells and monocytes treated in vitro concomitantly with cisplatin and rIFN-γ enhanced lysis of K562 cells. Lysis was dependent upon the duration of treatment. Cisplatin and rIFN-γ treated monocytes were equally cytotoxic to NK sensitive (K562) and NK resistant (Daudi & Raji) cell lines whereas NK cells were not rendered cytotoxic against NK resistant tumor cells. NK- and monocyte-mediated cytotoxicity against K562 cells was further enhanced when the effector cells were primed with rIFN-γ and were subsequently treated with cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=0025572458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025572458&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(90)90008-B

DO - 10.1016/0192-0561(90)90008-B

M3 - Article

C2 - 2127263

AN - SCOPUS:0025572458

VL - 12

SP - 893

EP - 898

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 8

ER -